Abstract

Isomeric pterocarpans, Dolichin A and Dolichin B of Macrotyloma uniflorum were docked with the three replication enzymes of HIV (Reverse transcriptase, Protease, Integrase). Analysed results proved that the docking score was high for Protease with Dolichin A (-6. 6899) and Dolichin B (-6. 6944) among Reverse transcriptase and Integrase. AIDS therapies could be scrutinized and /or replaced after the successful inihibitory effect of Dolichin. This study will support the cutting edge of HIV research and drug designing to find out a less side effect causing herbal formulations.

References

• Abhik Seal, Riju Aykkal, Rosana O Babu and Mriganka Ghosh (2011). Docking study of HIV-1 reverse transcriptase with phytochemicals. Bioinformation. 5(10): 430–439.
• Al-Mawsawi, L. Q. , Fikkert, V. , Dayam, R. , Witvrouw, M. , Burke, T. R. , Jr. ,
• Balakrishnan M, Srivastava R. C, Mayank Pokhriyal 2010. Homology Modelling and Docking Studies of HIV Protease. Journal of Biotechnology. 9: 96-100.
• Borchers, C. H. , and Neamati, N. (2006) Discovery of a small-molecule HIV-1 integrase inhibitor-binding site Proceedings of National Academy of Sciences U. S. A. 103:10080–10085
• Brik A & wong C H,(2003) HIV-1 protease: Mechanism and Drug discovery. Organic and Biomoleculat chemistry, 1: 5-14.
• Chen, R. , M. Yokoyama, H. Sato, C. Reilly, and L. M. Mansky. 2005. Human immunode?ciency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunode?ciency virus type 1 mutation frequencies. Journal of Virology 79:12045–12057.
• Cox, A. G. , and V. Nair. 2006. Novel HIV integrase inhibitors with anti-HIV activity: insights into integrase inhibition from docking studies. Antiviral Chemistry and Chemotherapy 17:343-35.
• Engler T. A. , LaTessa K. O. , Iyengar R. , Chai W. , Agrios K (1996). Seteroselective syntheses of substituted pterocarpans with anti-HIV activity, and 5-aza-/5-thia-pterocarpan and 2-aryl-2,3-dihydrobenzofuran analogues. Bioorganic and Medicinal Chemistry 4(10):1755-1769
• Huang, H. , Chopra, R. , Verdine, G. L. , and Harrison, S. C. (1998) Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance. Science 282, 1669 –1675
• Imming P, Sinning C, Meyer A: 2006 Drugs, their targets and the nature and number of drug targets. Nature Review Drug Discovery Oct;5(10):821-34.
• Ingham , J. L. ,Keen , N. T. ,Markham, K. R. and Mulheirn, L. J . (1981) Dolichins A and B, Two Pterocarpans from bacteria treated leaves of Dolichos biflorus. Journal of phytochemistry 20. 807
• Jorgensen W. L and Duffy E. M. 2000. Prediction of Drug solubility from Monte Carlo simulations Bioorganic Medicinal Chemistry Letters 10,1155-1158.
• Kohl N E, Emini E A, Schleif W A, Davis L J, Davis J C(1988). Active Human Immunodeficiency virus protease is required for viral infectivity, Proceedings of the National Academy of Sciences USA, 85: 4686-4689.
• M. L. Barreca, A. carotti, A. carrieri, A. Chimirri, A. M. Monforte, M. Pellegrini Calace and A. Rao 1999. Comparative Molecular Field Analysis (CoMFA) and Docking Studies of Non- nucleoside HIV RT inhibitors (NNIs). Bioorganic Medicinal Chemistry 7(1999):2283-2292.
• Lipinski CA, Lombardo F, Dominy BM, Feeney PJ. 2001. Experimental and Computational approaches to estimate solubility and permeability in Drug Discovery and Development setting. Advance Drug Delivery Reviews 1;46(1-3) 3-26.
• Overington JP, Al-Lazikani B, Hopkins AL. 2006: How many drug targets are there? Nature Reviews Drug Discovery. Dec;5(12):993-6.
• Pata J, Stritan W G, Steven G Goldstien and Thomas A. Stiez 2004. Structure of HIV – 1 Reverse Transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other non nucleoside inhibitors. Proceedings of the National Academy of Sciences. 101(29):10548-10553.
• Rajendra Kumar and Prabha Garg. 2010. Active site binding interactions of ?- Carboline derivative for HIV reverse transcriptase, protease and integrase. International journal of Drug Discovery 2(2): 51-55.
• Robinson, W. E. , Jr. , Reinecke, M. G. , Abdel-Malek, S. , Jia, Q. & Chow, S. A(1996) Inhibitors of HIV-1 replication that inhibit HIV integrase. Proceedings of National Academy of Sciences. USA 93, 6326–6331.
• Sarafianos G. Stefan, Bruno Marchand, Kalyan Das, Daniel Himmel, Michael A. Parnik, Stephen H. Hughes, and Eddy Arnold. 2010. Structure and function of HIV 1 reverse transcriptase: Molecular mechanisms of polymerization and inhibition. Journal of Molecular Biology. 23: 385(3): 693-713.
• Sengupta D, Verma D, Pradeep K Nair. 2007. Binding Modes, Binding Affinities, and ADME screening of HIV-1 NNRTI inhibitor Efavirnez and it analogues. Online Journal of Bioinformatics 8(1):99-114.
• Sengupta D, Verma D, Pradeep K Nair. 2008. Docking – MM- GB/SA and ADME screening of HIV-1 NNRTI inhibitor nevirapine and its analogues. In silico Biology, 8 ,0023.
• Ye XY, Ng TB. 2001 Peptides from pinto bean and red bean with sequence homology to cowpea 10- KDa protein precursor exhibit antifungal, mitogenic and HIV-1 Reverse Transcriptase – inhibitory activities. Biochemical and Biophysical Research Communication. 282:424-9.
• Ye XY, Ng TB. 2002. Isolation of a new cyclophilin-like protein from chickpeas with mitogenic, antifungal and anti – HIV-1 reverse transcriptase activities . Life sciences. 70: 1129-38.
• Ye XY, Ng TB. 2002 Delandin, a chitinase-like protein with antifungal, HIV-1 Reverse Transcriptase inhibitory activity and mitogenic activities from the rice bean Delandia umbellate. Protein Expression and Purification. 24: 524-9.